- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
IV magnesium sulfate treatment may lead to subsequent hospitalization in children with asthma: JAMA
Researchers studied 816 children and found that receiving intravenous magnesium in the emergency department was linked to subsequent hospitalization among children with asthma, compared with not receiving the therapy.
Ontario, Canada: The administration of intravenous (IV) magnesium sulfate in the emergency department (ED) is recommended for the treatment of refractory pediatric asthma. Now a recent study in JAMA Network Open has shown IV magnesium sulfate to be associated with subsequent hospitalization among children with asthma.
Guidelines have recommended the administration of IV magnesium sulfate for refractory pediatric asthma, despite this, the number of asthma-related hospitalizations has remained stable, and IV magnesium therapy is independently associated with hospitalization.
Against the above background, Suzanne Schuh, University of Toronto, Toronto, Ontario, Canada, and colleagues aimed to examine the association between IV magnesium therapy administered in the ED and subsequent hospitalization among pediatric patients with refractory acute asthma after adjustment for patient-level variables.
For this purpose, the researchers conducted a post hoc secondary analysis of a double-blind randomized clinical trial of children with acute asthma treated from September 26, 2011, to November 19, 2019, at 7 Canadian tertiary care pediatric EDs between September and November 2020. It included 816 otherwise healthy children aged 2 to 17 years with Pediatric Respiratory Assessment Measure (PRAM) scores of 5 points or higher after initial therapy with systemic corticosteroids and inhaled albuterol with ipratropium bromide. They were randomly assigned to 3 nebulized treatments of albuterol plus either magnesium sulfate (40-75 mg/kg) or a 5.5% saline placebo.
The research yielded the following findings:
- 26.3% received IV magnesium, and 88.4% of these children were hospitalized compared with 29.0% who did not receive IV magnesium.
- Multivariable factors associated with hospitalization were IV magnesium receipt from 2011 to 2016 (odds ratio [OR], 22.67) and from 2017 to 2019 (OR, 4.19), use of additional albuterol (OR, 5.94), and increase in PRAM score at disposition (per 1-U increase: OR, 2.24).
- In children with a disposition PRAM score of 3 or lower, receipt of IV magnesium therapy was associated with hospitalization (OR, 8.52).
In this secondary analysis of an RCT, the researchers found that the administration of IV magnesium therapy among children with refractory acute asthma was associated with hospitalization independent of asthma severity and other patient-level characteristics. After adjustment for patient-level characteristics, this association was also evident among children who met the criteria for hospital discharge at the time of ED disposition.
"Future research on the benefit of IV magnesium therapy in reducing hospitalization and the related safety profile may clarify the role of this therapy in refractory pediatric asthma," concluded the authors.
Reference:
The study titled, "Association Between Intravenous Magnesium Therapy in the Emergency Department and Subsequent Hospitalization Among Pediatric Patients With Refractory Acute Asthma: Secondary Analysis of a Randomized Clinical Trial," is published in JAMA Network Open.
DOI: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782049
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751